David Brown, MD
Rheumatology · Hyannis, MANPI 1225071962
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Novartis at 46.0% of the total. Reporting peaked in 2019 at $23,527 and has fallen 77.2% since, to $5,354 in 2025. Among rheumatology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,210 payments — averaging $46.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$26K
- Amgen$6K
- Johnson & Johnson$5K
- AbbVie$3K
- UCB, Inc.$2K
- Lilly USA, LLC$2K
- plus $11K from 28 others
What the payments were for
- Consulting fees$9,09316%
- Speaking & faculty fees$11,23520%
- Travel & lodging$3,1626%
- Food & beverage$32,02557%
- Education$5571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 87 | $25,797 |
| Amgen(2 entities) | 215 | $6,248 |
| Johnson & Johnson | 180 | $5,443 |
| AbbVie | 138 | $3,389 |
| UCB, Inc. | 94 | $2,201 |
| Lilly USA, LLC | 69 | $1,796 |
| Mallinckrodt Hospital Products Inc. | 43 | $1,662 |
| Genentech USA, Inc. | 69 | $1,381 |
| Pfizer | 76 | $1,241 |
| AstraZeneca(2 entities) | 43 | $1,200 |
| Janssen Scientific Affairs, LLC | 9 | $970 |
| GSK | 24 | $727 |
| Sobi, Inc | 29 | $660 |
| Boehringer Ingelheim | 17 | $634 |
| E.r. Squibb & Sons, L.L.C. | 23 | $473 |
| Fresenius Kabi USA, LLC | 12 | $377 |
| Sanofi | 10 | $257 |
| Regeneron Healthcare Solutions, Inc. | 8 | $249 |
| Fidia Pharma USA Inc. | 10 | $170 |
| Genentech, Inc. | 4 | $160 |
| ANI Pharmaceuticals, Inc. | 7 | $154 |
| Bioventus LLC | 6 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $121 |
| Organon | 6 | $113 |
| Antares Pharma, Inc. | 5 | $96 |
| Sandoz | 4 | $92 |
| Radius Health, Inc. | 4 | $77 |
| Actelion Pharmaceuticals US, Inc. | 2 | $51 |
| Pacira Therapeutics, Inc. | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Ultragenyx Pharmaceutical Inc. | 2 | $43 |
| Aurinia Pharma U.S., Inc. | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Baudax Bio Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,073 in reported general payments places this provider in the 90th percentile of 265 rheumatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 106 | $904,847 |
| Humira(Cf) PenAdalimumab | 100 | $675,926 |
| IlarisCanakinumab/Pf | 13 | $499,350 |
| EnbrelEtanercept | 20 | $152,794 |
| Xeljanz XrTofacitinib Citrate | 18 | $112,726 |
| Cosentyx Sensoready PenSecukinumab | 15 | $107,811 |
| KevzaraSarilumab | 17 | $98,100 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $94,801 |
| Humira PenAdalimumab | 13 | $88,742 |
| SimponiGolimumab | 11 | $65,377 |
| Orencia ClickjectAbatacept | 11 | $60,916 |
| SaphneloAnifrolumab-Fnia | 12 | $57,575 |
| ProliaDenosumab | 32 | $55,453 |
| RasuvoMethotrexate/Pf | 38 | $21,829 |
| MethotrexateMethotrexate Sodium | 528 | $16,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisIlaris | $25,797 | $499,35013 claims |
| AmgenEnbrel, Prolia | $6,248 | $208,24752 claims |
| SanofiKevzara | $257 | $98,10017 claims |
| Johnson & JohnsonSimponi | $5,443 | $65,37711 claims |
| AstraZenecaSaphnelo | $1,200 | $57,57512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 rheumatology providers in Massachusetts.
Other rheumatology in Hyannis
- Marilyn PikeBoston$1.4M
- John StoneBoston$926K
- Lee SimonBoston$600K
- Jeffrey SparksBoston$299K
- Ronald RapoportFall River$293K
- Richard ChouPalmer$270K
- Tanya LaidlawBoston$244K
- Tuhina NeogiBoston$242K
- Michael WeinblattBoston$228K
- Thomas GoodmanGroton$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.